Arcutis Biotherapeutics (ARQT) Operating Income (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Operating Income of -$9.1 million for Q1 2026, up 62.95% year-over-year from -$5.6 million in Q1 2025, and down 149.43% quarter-over-quarter from $18.4 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Operating Income (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$9.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 62.95% year-over-year to -$9.1 million; the TTM figure through Mar 2026 stood at $3.2 million (up 102.65% YoY), while the FY2025 annual figure was -$12.2 million, up 90.48% from the prior year.
- Operating Income for Q1 2026 stood at -$9.1 million, down from $18.4 million in the prior quarter.
- The five-year high for Operating Income was $18.4 million in Q4 2025, with the low at -$104.7 million in Q3 2022.
- The 5-year median for Operating Income is -$39.1 million (2024), against an average of -$40.7 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income sank 83.52% in 2022, then surged 340.92% in 2025.
- Arcutis Biotherapeutics' Operating Income stood at -$68.4 million in 2022, then advanced by 10.6% to -$61.2 million in 2023, then surged by 87.52% to -$7.6 million in 2024, then soared by 340.92% to $18.4 million in 2025, then plunged by 149.43% to -$9.1 million in 2026.
- Business Quant data shows ARQT's Operating Income at -$9.1 million in Q1 2026, $18.4 million in Q4 2025, and $8.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 16.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.43 Mn |
| Mar 31, 2026 | -9.09 Mn |
| Dec 31, 2025 | 18.39 Mn |
| Sep 30, 2025 | 8.53 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -7.63 Mn |
| Sep 30, 2024 | -39.07 Mn |
| Jun 30, 2024 | -50.08 Mn |
| Mar 31, 2024 | -31.62 Mn |
| Dec 31, 2023 | -61.17 Mn |
| Sep 30, 2023 | -36.90 Mn |
| Jun 30, 2023 | -66.76 Mn |
| Mar 31, 2023 | -76.27 Mn |
| Dec 31, 2022 | -68.42 Mn |
| Sep 30, 2022 | -104.75 Mn |
| Jun 30, 2022 | -65.83 Mn |
| Mar 31, 2022 | -62.63 Mn |
| Dec 31, 2021 | -71.29 Mn |
| Sep 30, 2021 | -57.08 Mn |